There have been multiple systemic innovations that have improved how we treat non-small cell lung cancer (NSCLC). First came targeted therapies in the 1970s and 1980s and then immunotherapies, which first entered the market roughly a decade ago. More recently, surgical robots have enabled better nodule removal.
Despite these, lung cancer is still the number one cause of cancer death worldwide.
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?